Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Polysorbate 80 - reference spectrum, Qty : n/a

Polysorbate 80 - reference spectrum, Qty : n/a

NA

DISCOVER
TETRAZEPAM IMPURITY C CRS (20MG)

TETRAZEPAM IMPURITY C CRS (20MG)

NA

DISCOVER
FLUPHENAZINE ENANTATE CRS (100 MG)

FLUPHENAZINE ENANTATE CRS (100 MG)

2746-81-8

DISCOVER
PERGOLIDE MESILATE CRS (150 MG)

PERGOLIDE MESILATE CRS (150 MG)

66104-23-2

DISCOVER
HYMECROMONE CRS (100 MG)

HYMECROMONE CRS (100 MG)

90-33-5

DISCOVER
HYMECROMONE IMPURITY A CRS (25 MG)

HYMECROMONE IMPURITY A CRS (25 MG)

108-46-3

DISCOVER
HYMECROMONE IMPURITY B CRS (25 MG)

HYMECROMONE IMPURITY B CRS (25 MG)

NA

DISCOVER
TETRAZEPAM - REFERENCE SPECTRUM (N/A)

TETRAZEPAM - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
PROPOFOL CRS (650 MG)

PROPOFOL CRS (650 MG)

2078-54-8

DISCOVER
PROPOFOL FOR PEAK IDENTIFICATION CRS (0.1 ML)

PROPOFOL FOR PEAK IDENTIFICATION CRS (0.1 ML)

2078-54-8

DISCOVER
PROPOFOL IMPURITY J CRS (20 MG)

PROPOFOL IMPURITY J CRS (20 MG)

NA

DISCOVER
4-D-SER-GOSERELIN CRS (0.1 MG)

4-D-SER-GOSERELIN CRS (0.1 MG)

NA

DISCOVER